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Abstract 
Follicular Lymphoma (FL) is the second most frequent non-Hodgkin lymphoma accounting for approximately 
10-20% of all lymphomas in Western Countries. Histologic transformation (HT) is a frequent event in the clini-
cal course of patients with indolent lymphoma that is often accompanied by a dramatic change in the clinical fea-
tures of the disease towards a more aggressive course. Although the transformation of Follicular Lymphoma 
(tFL) was described several decades ago, there is a strong need for a better understanding of both the dynamics 
of the tumor clonal evolution and the genetic events  leading to ()transformation. In addition, the management 
of patients with tFL is challenged by the heterogeneity of the previous treatments. The present review describes 
the state of art of tFL, outlining recent advances in the understanding of genetic basis and the evolutionary pro-
cess governing the initiation and persistence of tumor evolution. It will be also addressed the key questions pend-
ing on this incurable disease, such as a lack of a standard therapeutic strategy for tFL patients as well as its out-
come in the Rituximab (R) era. 
 
Keywords: Non Hodgkin Lymphoma, Follicular Lymphoma, Transformed Follicular Lymphoma, 
immunochemotherapy 
 
 
 
Introduction 
 
Follicular Lymphoma is defined by the World 
Health Organization (WHO) classification 
(Swerdllow SH, Campo E 2008) as a “neoplasm 
composed of follicle center (germinal center – 
GC) B cells, typically both centrocytes and 
centroblasts which usually has at least a partially 
follicular pattern”. FL arises then by a malig-
nant transformation of the normal germinal 
center B cells and therefore carries the charac-
teristics of centrocytic/centroblastic morpholo-
gy. 
The disease is usually characterized by an indo-
lent clinical course, excellent response to initial 
therapy with frequent relapses and shorter du-
ration responses to salvage therapy.  
At present, thanks to the advances in the treat-
ment of FL, the disease is moving from an in-
curable to curable one. Regarding the manage-
ment chemoimmunotherapy – usually followed 
by Rituximab maintenance – is the standard of 
care; whereas patients with nonbulky or asymp-
tomatic disease may be treated with Rituximab 
monotherapy or simply observed (Jonathan W 
Friedberg et al. 2009). Although many asymp-
tomatic patients with low-volume disease may 
not require early therapy and can be observed, 
the majority of patients will lastly experience 
disease progression and will need therapy dur-
ing the course of the disease. In particular, 
some patients have long-term remission lasting 
years, others have a rapidly progression of the 
disease and develop treatment resistance 
and/or transformation to aggressive lymphoma 
(Link et al. 2013; S. M. Smith 2013). Priorities 
in goals of care include avoiding relapses, trans-
formation to aggressive subtypes and death.  
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In the past, approximately 25% of cases trans-
form to aggressive disease, mostly  Diffuse 
Large B-cell Lymphoma (DLBCL),with a very 
poor prognosis (Montoto et al. 2007). The his-
tologic changes seen in patients with HT are, in 
the great majority of cases, accompanied by a 
change in the clinical features of the disease to-
wards a more aggressive course (Montoto 
2015). 
 More recently, contradictory data are emerging 
with respect to the impact of initial treatment  
on the risk of transformation (Montoto 2015), 
In particular, the adoption of Rituximab in first 
line therapy seems associated with a lower risk 
of transformation. Therefore, decisions on the 
management of tFL patients come from ex-
trapolation data of retrospective studies or from 
prospective trials in DLBCL, as this is the 
commonest transformed lymphoma. 
The present review will be focused on the state 
of art of tFL and will try to address pending 
questions about this condition. 
 
 
Definition of tFL 
 
Definition of tFL is still a great challenge as it 
varies among different series. Over the past 
years, definition of transformation have been 
largely varying from “an histological features of 
DLBCL as opposed to cytologic progression with an 
increase in the proportion of large cells (from grade 1/2 
to grade 3 FL)” (Montoto et al. 2007) to “refracto-
ry/recurrent disease with either clinical or pathologic di-
agnosis of transformed lymphoma” (Link et al. 2013); 
passing through other definitions. The main is-
sue in considering a unique definition is the fact 
that transformation is diagnosed in different se-
ries based on cytological samples, on histologic 
samples or in some cases on clinical grounds 
alone. Indeed  diagnosis should be based on bi-
opsy or adopting clinical criteria in the cases in 
which it is not  possible to obtain a biopsy, ei-
ther because of the poor performance status of 
the patient or because of progression of the 
disease in inaccessible areas (Montoto and Fitz-
gibbon 2011). In 2008, Al-Tourah et al. (Al-
Tourah et al. 2008) published clinical criteria to 
define transformation: a rapid discordant lym-
phadenopathy growth, unusual sites of extra-
nodal involvements, a sudden rise in the LDH 
level, hypercalcemia, or presence of new B-
symptoms. 
 
Incidence, Prognosis and Outcome of tFL 
 
Historically, transformation was largely consid-
ered a catastrophic event. Although the clinical 
course of FL patients may span more than ten 
years, transformation occurrence heralds a 
change from an indolent to an aggressive dis-
ease course, and is associated with major mor-
bidity and mortality (14). In particular, most of 
the studies have reported a poor prognosis after 
transformation, with a median duration of sur-
vival generally ranging from 2.5 months to 2 
years, with most deaths being due to lymphoma 
(5,7,12,13,15–21).  
The incidence of HT have wavered over the 
past several decades, due to the adoption of dif-
ferent diagnostic methods, definition of trans-
formation and duration of follow-up. Thus, the 
considerable variability in the incidence of tFL 
reported in literature may be explained by the 
heterogeneity in the definition of transfor-
mation, population included and diagnostic 
tools. 
The clinical significance of transformation was 
seen in 325 FL patients from the St Bartholo-
mew’s Hospital of London, in which the risk of 
transformation by 10 years was 28% and the 
median survival after transformation was 1.2 
years. Patients with tFL  had a significantly 
shorter OS and a shorter survival from progres-
sion compared to others (Montoto et al. 2007). 
Al-Tourah et al. analyzed the incidence of HT 
in a population based-study of 600 patients. 
The annual risk of transformation was estimat-
ed to be 3% per year, and the median survival 
after transformation was 1.7 years (7).  
In another recent study from the University of 
Iowa/Mayo Clinic (Link et al. 2013), the cumu-
lative risk of transformation and death without 
transformation (competing risk) increased 
steadily over time up through 5 years of follow-
up and then appeared to slow, with only four 
transformations observed beyond 5 years from 
diagnosis. Transformation rate at 5 years was 
highest in patients who were initially observed 
and lowest in patients who initially received 
Rituximab monotherapy (Link et al. 2013). 
However, in a group of 107 patients with ad-
vanced FL and low tumor burden registered in 
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the F2 database and managed with a W&W pol-
icy, the 5-year risk of transformation was quite 
low. After a median follow-up of 64 months, 
five patients experienced transformation to ag-
gressive non-Hodgkin lymphoma, two during 
the W&W no treatment period and three after 
progression, with an estimated rate of less than 
1% per year (Solal-Céligny et al. 2012). 
Wagner-Johnston et al. have investigated the 
incidence, prognostic features, and outcomes 
associated with tFL among 2652 patients with 
FL prospectively enrolled in the US National 
LymphoCare Study. At a median follow-up of 
6.8 years, 14.3% of patients underwent trans-
formation; patients who were treated at diagno-
sis had a reduced risk of transformation as well 
as maintenance Rituximab was associated with 
reduced transformation risk. The median  OS 
post transformation was 5 years (Wagner-
Johnston et al. 2015).  
The clinical and laboratory findings with better 
Overall Survival (OS) at the time of transfor-
mation include normal LDH levels, limited dis-
ease extent, good performance status, absence 
of B symptoms, fewer number of previous re-
lapses, transformation after expectant manage-
ment, having had no prior CR, or having had 
no response to salvage chemotherapy 
(5,7,12,13).  
Despite the overall poor outcome of tFL pa-
tients, Yuen et al., identified a subset of patients 
having a relatively good outcome (Yuen et al. 
1995). Limited extent of disease, attainment of 
Complete Remission (CR) to treatment given at 
the time of transformation and no prior therapy 
had a particularly favorable prognosis. In addi-
tion, patients who achieved CR after transfor-
mation had a better OS than those with ad-
vanced stage disease (108 vs 18 months) (Yuen 
et al. 1995). The impact of limited disease on 
tFL patients’ prognosis was also seen by Basti-
on et al., (Bastion et al. 1997) and Al-Tourah et 
al.,(Al-Tourah et al. 2008). This latter group 
shown that the 5-year OS was 66% for patients 
with a limited transformation compared to 19% 
for those with advanced-stage at transformation 
in a significant way (Al-Tourah et al. 2008). 
Only slight improvement were observed in re-
cent studies, mostly showing the shorter OS of 
tFL patients in comparison to non-transformed 
FL patients. This adverse effect of transfor-
mation on survival was clearly illustrated by Al-
Tourah et al., where the 10-year OS for non-
transformed FL patients was 75%, whereas was 
only 36% for tFL patients were alive 10 years 
from the time of their initial FL diagnosis (Al-
Tourah et al. 2008). Similar behaviors were also 
seen in other studies (Montoto et al. 2007).  
Importantly, most of the patients in the report-
ed studies received therapies not incorporating 
Rituximab. However, differences in patients’ 
series, treatment and outcome is not a good 
condition to take advantage of; a lot of work is 
still needed to find out standard clinical criteria. 
Table 1 summarizes transformation risk in re-
cent series. 
 
Table 1. Outcome of tFL patients in recent series  
 
Studies Transformation risk 
Montoto et al., 2007 17% at 5 years (100% biopsy proven) 
1.9 RR in W&W 
Al-Tourah et al., 2008 18% at 5 years (63% biopsy proven) 
30% at 10 years 
(18% Doxo vs 30% Alk P=0.001) 
Link et al., 2008 10.7% at 5 years (85% biopsy proven) 
14.4% in W&W 
3.2% in Rituximab 
Wagner et al., 2005 12.8% at 5 years (39% biopsy) 
13.4% Rituximab chemotherapy 
18.3% NonRituximab chemotherapy 
Sarkozi et al., 2016 4.1% at 6 years (100% biopsy proven) 
 
 
 Can we assess any improvement in the outcome of tFL 
in the Rituximab era? 
 
Whether the addition of Rituximab in intial 
treatment modifies the outcome of tFL pa-
tients, still needs to be addressed. However, 
over the last 5 years, several  studies have been 
suggesting that the outcome of tFL patients has 
improve in the Rituximab era (Conconi et al. 
2012; Ban-Hoefen et al. 2013; Lerch et al. 2015; 
Link et al. 2013; Guirguis et al. 2014). 
Very recently Sarkozy and all analyzed risk fac-
tors, incidence and outcome of HT at first re-
currence in the PRIMA patient cohort: after 6 
years after a chemoimmunotherapy induction, 
the cumulative incidence of HT was 4.1% (Sar-
kozy et al. 2016). 
Literature suggests that patients treated with 
Rituximab-containing chemotherapy achieve a 
longer OS compared with retrospective cohorts 
of patients treated with chemotherapy alone 
(Link et al. 2013; Bastion et al. 1997). In con-
trast, the most recent trial comparing a W&W 
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approach vs R did not show any differences in 
terms of risk of transformation (Ardeshna et al. 
2014). As commented by the same authors, in 
the most of the reported series, the majority of 
patients have received chemotherapy prior to 
the diagnosis of HT and have advanced stage at 
the time of transformation  so the better out-
come cannot be attributed to an earlier identifi-
cation of transformation leading to a better risk 
population (Montoto 2015).  
Controversial results were also found in wheth-
er prior treatment with Rituximab has a good 
effect on the outcome after transformation. In 
a recent study, Lerch et al. (Lerch et al. 2015), 
showed that the treatment with Rituximab be-
fore the diagnosis of tFL was not correlated 
with a worse outcome in those patients. In con-
trast, patients with relapsed DLBCL treated 
with Rituximab have a significantly worse 
prognosis at progression (Montoto 2015). Oth-
er two studies demonstrated that prior R treat-
ment did not result in a worse outcome in tFL 
patients who received high dose therapy with 
autologous stem cell rescue (HDT-ASCR) 
(Ban-Hoefen et al. 2013; Madsen et al. 2015). 
Patients who have previously received CHOP 
(Rituximab, Cyclophosphamide, 
Hydroxydaunorubicin, Vincistrine [Oncovin], 
Prednisone) chemotherapy, with or without R, 
are frequently treated with second line regimens 
for DLBCL (Montoto 2015). 
The role of Rituximab maintenance in DLBCL 
patients is also still unconcluded. In a recent 
study, R Maintenance was associated with re-
duced transformation risk. The median  OS 
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clude chromosomal alterations that result from 
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Recent whole-exome studies have highlighted 
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Some of these data derived from genetic meth-
ods, and suggest that FL may evolve as a “non 
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Wartenberg et al. 2013; Green et al. 2013; Eide 
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related to a common progenitor than the clone 
predominating at the time (or site) of prior 
sampling (Casulo, Burack, and Friedberg 2015). 
The clonal evolution models to tFL were de-
fined by investigating genomic alterations that 
are present in the dominant clone of both pre- 
and post- specimens (“Shared lesions”), and 
contrasting them to those that are present ex-
clusively in the FL or tFL  biopsy (“phase-
specific lesions”). This analysis allowed to dis-
criminate between i. a linear model, in which 
the tFL dominant clone will maintain all lesions 
present in the original FL clone, in combination 
with additional tFL-acquired alterations; ii. a di-
vergent evolution model, where there are le-
sions that are unique to the dominant clone of 
the FL or the tFL, in addition to the set of 
shared alterations (Pasqualucci et al. 2014).  
 
Thus, data mostly supported a divergent evolu-
tion model in a significant proportion of pa-
tients undergoing transformation, whereby FL 
and tFL arise from a common mutated ancestor 
through the independent acquisition of distinct 
lesions (Pasqualucci et al. 2014). Most FL and 
tFL derive from a common mutated precursor 
cell through divergent clonal evolution. There 
are some shared molecular determinants such 
as chromatin modification and apoptosis and 
some tFL specific determinants such as cell cy-
cle, proliferation and DNA damage response.  
Interestingly, the most commonly affected 
genes in both FL and tFL where those encod-
ing for histone/chromatin modification en-
zymes, including methyltransferases and 
acetyltransferases (Pasqualucci et al. 2014). The-
se early lesions in FL generally affect epigenetic 
regulators (genes controlling chromatin struc-
ture), including  the H3H4 trimethyl-transferase 
MLL2 mutation, never lost at transformation, 
EZH2 and the acetyltransferases CREBBP and 
EP300 (Okosun et al. 2014; Pasqualucci et al. 
2014; Morin et al. 2010; Morin et al. 2011). 
Other frequent dysregulation in both FL and 
tFL was represented by programmed cell death 
genes, in particular BCL2 translocations, and 
thus presumably in the common ancestor clone 
(Pasqualucci et al. 2014). 
Among tFL specific determinants there were 
alterations of cell cycle control, through muta-
tion or deletion of cyclin-dependent kinase 
2A/B (CDKN2A/B). These latter are two tu-
mor suppressor genes, whose protein products 
p14-ARF, p16-INK4A and p15-INK4B, are  
important for negative regulation of cell cycle 
G1 progression and stabilization of the tumor 
suppressor p53 (Pasqualucci et al. 2014; Sherr 
2004).  
Alterations in Myc (Okosun et al. 2014; 
Pasqualucci et al. 2014), as well as DNA dam-
age response, through losses of genes associat-
ed with regulation of the immune response, 
were also consistent in tFL only. Among the 
mutations that affect the immune response, re-
cent studies found the entire HLA class I locus, 
specifically in β-2-microglobulin (B2M) and 
CD58 (Pasqualucci et al. 2014; Bouska et al. 
2014; Morin et al. 2010).   
 
Although a large number of prognostic markers 
have been implicated as contributing to survival 
in FL, only a handful have specifically examined 
the role of biological factors impacting risk of 
transformation. 
It is becoming evident that phenotype varia-
tions related to genetics events (MYC, BCL2, 
p16, p53) should be routinely identified. FISH 
analysis could also be required to identify genet-
ic alterations in MYC, BCL2 and BCL6. 
The incidence of CD30 expression in tFL has 
also been reported to be 20% in a recent retro-
spective series of cases and CD30 expression 
should be also routinely identified by IHQ.  
In summary, there is not a single mechanism 
driving transformation from FL to DLBCL (O-
kosun et al. 2014; Pasqualucci et al. 2014; Bou-
ska et al. 2014; Andrew J. Davies et al. 2007). 
Rather, there are several mechanisms involved 
in transformation. 
 
Treatment of tFL 
Optimal treatment strategies for tFL still repre-
sents an unmet need. Unfortunately, most clini-
cal trials exclude patients with tFL and there are 
no randomized studies in the modern era, with 
the result that level of evidence is very limited. 
In historic series, as described before, the out-
come of tFL patients was very poor, with a me-
dian OS of approximately 1 or 2 years 
(Montoto and Fitzgibbon 2011). However, the 
majority of published studies were conducted in 
the pre-Rituximab era, making difficult to draw 
any conclusion on the current scenario.  
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In the study conducted by Lynk and colleagues  
in 60 out of 631 patients with biopsy-proven 
tFL, the median OS was 50 months with an OS 
rate of 73% at 5 years after treatment with R-
CHOP chemotherapy (Link et al. 2013). Sur-
vival was similarly in the National Comprehen-
sive Cancer Network (NCCN) database study, 
with a median OS around 5 years in 118 biopsy 
confirmed tFL patients, was (Ban-Hoefen et al. 
2013). Similar results were seen in early-stage 
FL experiencing tFL, with a 3-year OS of 44% 
(Bains et al. 2013). The estimated median OS 
for the patients with a histological diagnosis of 
HT from the PRIMA trial was 3.8 years after a 
median 6 yea follow up (Sarkozy et al. 2016). 
As response after conventional chemotherapy, 
high-dose therapy (HDT) and autologous stem 
cell transplantation (ASCT) has been studied by 
several research groups (Witzig et al. 2002; 
Schouten et al. 1989; Freedman et al. 1991; 
Foran et al. 1998; Berglund et al. 2000; Chen et 
al. 2001; Williams et al. 2001; J W Friedberg et 
al. 1999; Andreadis et al. 2005; Sabloff et al. 
2007; Ramadan KM, Connors JM 2008).  
 Of historical relevance, the efficacy of ASCT 
was shown in tFL patients in old phase 2 and 
transplant registry series prior to the incorpora-
tion of immunotherapy (Wang and Hou 2010; 
Montoto and Fitzgibbon 2011). In particular, 
40% of patients experienced long-term benefit, 
with survival rates similar to patients with re-
lapsed aggressive lymphoma receiving the same 
treatment (Williams et al. 2001). However, most 
of the transplant studies are based on only small 
retrospective series of 20 to 50 patients 
(Hamadani et al. 2008; Williams et al. 2001; 
Chen et al. 2001; J W Friedberg et al. 1999; 
Sabloff et al. 2007). The role of ASCT has been 
further investigated in the Rituximab era, and 
so more relevant  to current practice with the 
result that the addition of the antibody  has im-
proved the outcomes of tFL patients practice.  
The Canadian Bone Marrow Transplant group 
(CBMTG) analyzed 172 patients with tFL ,  53 
treated with rituximab containing chemothera-
py  alone  and  97 underwent instead ASCT.  
This latter approach improved OS and Progres-
sion Free Survival (PFS) of patients over Ritux-
imab-containing chemotherapy regimens, alt-
hough the difference was modest (Villa et al. 
2013). Other groups observed that patients who 
were Rituximab naïve prior to ASCT, seemed 
to achieve better results than those with prior 
Rituximab exposure (Wirk et al. 2014; Kuruvilla 
et al. 2015; Ban-Hoefen et al. 2012; 
Gisselbrecht et al. 2010; Villa et al. 2013; Mad-
sen et al. 2015) paralleling the observation in de 
novo DLBCL patients undergoing ASCT 
(Gisselbrecht et al. 2010). In addition, patients 
with early tFL performed significantly better in 
terms of OS, compared to those with late 
tFL(Link et al. 2013). ASCT had similarly out-
comes in the large NCCN database, with an OS 
of 83% being superior compared to chemo-
therapy alone or ASCT without the incorpora-
tion of monoclonal antibodies (S. D. Smith et 
al. 2009; Villa et al. 2013).  
 
Allogeneic transplantation in tFL has been less 
well studied, with small numbers of patients in 
mostly retrospective series. Some of these stud-
ies showed significantly inferior results than 
ASCT (Ramadan KM, Connors JM 2008), most 
probably due to the higher treatment related 
mortality (TRM) associated with the allogenic 
approach (35% versus 10% at 5 years). In con-
trast, the risk of disease relapse at 5 years was 
tendentially lower. 
For relapses after ASCT, further salvage thera-
py with allogeneic transplantation seemed to 
improve the outcome of tFL regardless of the 
significant transplant related mortality  
(Ratanatharathorn et al. 1994; Doocey et al. 
2005). 
 
Radioimmunotherapy (RIT) has been proposed 
as primary treatment for tFL. In particular, ra-
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have previously received radiotherapy, it might 
be considered especially in patients not qualify-
ing for more aggressive approaches giving that 
CR patients have shown prolonged response, 
often longer than 1 year (Izidore S. Lossos and 
Gascoyne 2011).  
Moreover, an additional area of interest  in-
volves the integration of RIT with HDT and 
transplant in tFL patients, that has the potential 
to improve disease control, with similar toxici-
ties compare to HDT alone (Krishnan et al. 
2008; Wondergem et al. 2012; Reddy and 
Savani 2011; Mei et al. 2014).  
 
Recently, novel agents have been investigated in 
tFL. In a phase 2 study, Lenalidomide showed 
an overall response rate of 57%, with median 
response duration of over 1 year in tFL patients 
(Czuczman et al. 2011). Specific inhibitors, tar-
geting Aurora A kinase (alisertib) (Jonathan W. 
Friedberg et al. 2014), Bruton tyrosine kinase 
(ibrutinib) (Aalipour and Advani 2013), the ϑ 
isoform of phosphatidylinositol 3-kinase 
(idelalisib) (Gopal et al. 2014; Burger and 
Okkenhaug 2014) and the BCL2 protein 
(GDC-0199/ABT199) (Seymour JF et al. 2013), 
are currently being investigated in both indolent 
and aggressive lymphomas. These novel agents 
seem to have a significant impact on the out-
come of tFL patients.  
Recent efforts are focusing on the immune tol-
erance towards lymphoma cells as an alternative 
therapeutic approach. Pidilizumab is currently 
used as a monoclonal antibody to Programmed 
death-1 (PD-1), a member of the B7 receptor 
family that represents an important immune 
checkpoint regulator. Its efficacy has been re-
cently shown in ASCT patients with DLBCL, 
including a subset with tFL (Armand et al. 
2013). 
 
 
Conclusions 
 
HT is expected as a relatively frequent event in 
the clinical course of patients with indolent 
lymphoma. However, The incidence of HT var-
ies enormously amongst different series, pend-
ing on the definition of HT, which is different 
in different studies., and different treatment ap-
proaches of the FL. Based on the available pub-
lished studies, mostly derived from small retro-
spective studies, there is still not any standard 
therapeutic strategy for tFL patients: treatments 
used are different in different reports and rela-
tionship between treatment and outcome does 
not emerge very well from the literature. The 
fact that the risk of transformation is rarely an 
end-point in prospective studies underlined a 
great obstacle in this field, so there is no clear 
evidence that the initial management has an 
impact on the subsequent risk of transfor-
mation.  
In conclusion, There is need for further studies  
aiming to provide an answer to pending ques-
tion, including i. Definition of tFL; ii. 
Assessement of risk of transformation in non-
treated patients; iii. Potential role of a FL stem 
cell or repopulating cell as a potential cell of 
origin contributing to histologic transformation; 
iv. History of clonal evolution; v. Molecular de-
terminants; vi. Response to salvage therapy of 
tFL; vii. Outcome of tFL in the Rituximab era. 
In addition, other several questions should be 
addressed, such as whether De novo tFL is the 
same or a different disease; whether FL3b is 
different from tFL and if there are differences 
between tFL at first or subsequent relapse. 
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